Paclitaxel-Loaded Polymeric Micelle (230 mg/m2) and Cisplatin (60 mg/m2) vs. Paclitaxel (175 mg/m2) and Cisplatin (60 mg/m2) in Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase IIB Trial
| Autor: | Hee Joung Kim, Hee Sun Park, Sung Yong Lee, Sun Young Kim, Tae Won Jang, In-Jae Oh, Young Chul Kim, Kye Young Lee, Kwan Ho Lee, Young June Jeon, Kyu Sik Kim |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Urology Kaplan-Meier Estimate Pharmacology Disease-Free Survival chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Paclitaxel-Loaded Polymeric Micelle Lung cancer Micelles Aged Proportional Hazards Models Cisplatin Chemotherapy business.industry Combination chemotherapy Middle Aged medicine.disease Gemcitabine Oncology Tolerability chemistry Female business medicine.drug |
| Zdroj: | Clinical Lung Cancer. 14:275-282 |
| ISSN: | 1525-7304 |
| DOI: | 10.1016/j.cllc.2012.11.005 |
| Popis: | Introduction The development of paclitaxel-loaded polymeric micelle (PPM) has circumvented many of the infusion-related difficulties associated with standard solvent-based paclitaxel. PPM plus cisplatin combination chemotherapy showed significant antitumor activity in phase I and II studies. This prospective randomized controlled phase IIB study assessed the noninferiority of the efficacy and tolerability of high-dose PPM plus cisplatin to a standard dose of paclitaxel plus cisplatin. Patients and Methods Patients with stage IIIB/IV or recurrent non–small-cell lung cancer (NSCLC) who were chemonaive were eligible for participation. The patients were randomly assigned to receive PPM 230 mg/m 2 plus cisplatin 60 mg/m 2 or paclitaxel 175 mg/m 2 plus cisplatin 60 mg/m 2 once every 3-week cycle. The primary endpoint was to compare the response rate (RR) between the groups with coprimary analyses to assess noninferiority. Secondary endpoints included progression-free survival, overall survival, and safety. Results A total of 276 patients were randomized to PPM plus cisplatin (n = 140) or paclitaxel plus cisplatin (n = 136). RR was 43.6% in the PPM plus cisplatin group and 41.9% in the paclitaxel plus cisplatin group. Noninferiority of PPM plus cisplatin compared with paclitaxel plus cisplatin was confirmed for RR. There were no differences in progression-free survival and overall survival between the groups. Although there was a higher rate of grade 3 neutropenia in the PPM plus cisplatin group, the overall rate of adverse events was comparable between the 2 groups. Conclusion PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect